Aquinox(NLTX) - 2022 Q2 - Quarterly Report

Financial Performance - Research and development expenses for Q2 2022 were $11.0 million, an increase of 12% from $9.8 million in Q2 2021[81]. - Total operating expenses for the first half of 2022 were $31.2 million, a 4% increase from $30.1 million in the same period of 2021[79]. - General and administrative expenses for Q2 2022 were $4.9 million, a decrease of 7% from $5.3 million in Q2 2021[83]. - Interest income increased significantly to $194,000 for the three months ended June 30, 2022, compared to $5,000 for the same period in 2021, representing a 3780% increase[84]. - The company incurred net cash used in operating activities of $25.4 million for the six months ended June 30, 2022, compared to $26.6 million for the same period in 2021[85]. - The net loss for the six months ended June 30, 2022, was $31.0 million, adjusted for non-cash items including stock-based compensation of $4.8 million[88]. - Cash used in investing activities for the six months ended June 30, 2022, was $39.8 million, primarily for purchases of available-for-sale securities and laboratory equipment[89]. - The net change in cash, cash equivalents, and restricted cash for the six months ended June 30, 2022, was a decrease of $64.9 million[87]. - The company has not generated product revenue or achieved profitability since inception and expects to continue incurring net losses for the foreseeable future[92]. - The company believes its existing cash and investments will be sufficient to fund operations through 2023, but may need to seek additional funds sooner than planned[92]. - The company entered into an ATM Equity Offering Sales Agreement with BofA Securities for an aggregate offering price of up to $40.0 million, but no sales have been made to date[86]. Clinical Trials and Research - The Phase 1 clinical trial of NL-201 is planned to enroll up to 252 patients, with interim data expected to be disclosed in 2023[67][68]. - NL-201 is designed to enhance binding to the beta and gamma subunits of the IL-2 receptor while eliminating binding to CD25, aiming to reduce toxicity[62][65]. - The company plans to initiate a Phase 1 clinical trial in hematological malignancies, dependent on data from the ongoing solid tumor trial[69]. - The company is exploring new therapeutic candidates using de novo protein design, including targeted IL-2/IL-15 mimetics and T-Reg agonists[72]. Company Overview - The merger with Aquinox was completed on August 8, 2019, resulting in the renaming of the company to Neoleukin Therapeutics, Inc.[61]. - Cash-on-hand is expected to be sufficient to fund operations through 2023[75]. - The company is focused on maintaining research continuity during the COVID-19 pandemic while ensuring employee safety[76]. Future Outlook - The company’s future capital requirements will depend on various factors, including the development of product candidates and the costs of regulatory approvals[94].